“…On the whole, three newly updated meta-analyses revealed that there were no evidence supporting that XPD Lys751Gln polymorphism contributed to prostate cancer (Ma et al, 2013) , colorectal cancer (Zhang et al, 2011) , or gastric cancer (Yin et al, 2013). On the contrary, other large sample meta-analyses proposed a greater risk in hepatocellular carcinoma (Guo et al, 2012), breast cancer (Yan et al, 2014), lung cancer , glioma (Chen et al, 2012), and acute myeloid leukemia (AML) (Liu et al, 2014). For XPD Asp312Asn polymorphism, three meta-analyses proposed a greater risk in prostate cancer (Ma et al, 2013), gastric cancer (Yin et al, 2013), and esophageal cancer (Duan et al, 2012).…”